Pediatric Open Studies

Registry

COG-APEC14B1
Project: EveryChild - A Registry, Eligibility Screening, Biology and Outcome Study
https://clinicaltrials.gov/ct2/show/NCT02402244
Albert Kheradpour, MD

CNS

COG-ACNS1422
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
https://clinicaltrials.gov/ct2/show/NCT02724579
Albert Kheradpour, MD
National Children’s Hospital-Head Start IV
Newly Diagnosed Children (Less Than 10 Years Old) With Medulloblastoma And Other Central Nervous System Embryonal Tumors. Clinical And Molecular Risk-Tailored Intensive And Compressed Induction Chemotherapy Followed By Consolidation With Randomization To Either Single-Cycle Or To Three Tandem Cycles Of Marrow-Ablative Chemotherapy With Autologous Hematopoietic Progenitor Cell Rescue
https://clinicaltrials.gov/ct2/show/NCT02875314
Albert Kheradpour, MD
COG-ACNS1721
A Phase 2 Study of Veliparib (ABT-888, IND # 139199) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600E https://clinicaltrials.gov/ct2/show/NCT03581292
Albert Kheradpour, MD
COG-ACNS1723
A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly-Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG) (IND# 145355)
https://clinicaltrials.gov/ct2/show/NCT03919071
Albert Kheradpour, MD
COG-ACNS1831
A Phase 3 Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
http://clinicaltrials.gov/ct2/show/NCT03871257
Albert Kheradpour, MD
COG-ACNS1833
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
https://clinicaltrials.gov/ct2/show/NCT04166409
Albert Kheradpour, MD

Germ Cell

COG-A031102
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors 
https://clinicaltrials.gov/ct2/show/NCT02375204
Albert Kheradpour, MD
COG-AGCT1531
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
https://clinicaltrials.gov/ct2/show/NCT03067181
Albert Kheradpour, MD
COG-AGCT1532
A randomized phase 3 trial of accelerated versus standard BEP chemotherapy for patients with Intermediate and poor-risk metastatic germ cell tumors
https://clinicaltrials.gov/ct2/show/NCT02582697
Albert Kheradpour, MD

Leukemia

COG-AALL1521
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With  De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway–Mutant Acute Lymphoblastic Leukemia
https://clinicaltrials.gov/ct2/show/NCT02723994
Albert Kheradpour, MD
COG-AALL1631
International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones
https://clinicaltrials.gov/ct2/show/NCT03007147
Albert Kheradpour, MD
COG-AAML1531
Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
https://clinicaltrials.gov/ct2/show/NCT02521493
Albert Kheradpour, MD
COG-AALL1732
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL; Risk Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
https://clinicaltrials.gov/ct2/show/NCT03959085
Albert Kheradpour, MD
COG-ADVL1822
A Phase 1/2, Multicenter, Dose-Escalating Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy Of Quizartinib Administered in Combination with Re-Induction Chemotherapy, and as a Single-Agent Continuation Therapy, in Pediatric Relapsed/Refractory AML Subjects Aged 1 Month to <18 Years (and Young Adults Aged up to 21 Years) with FLT3-ITD Mutations
https://clinicaltrials.gov/ct2/show/NCT03793478
Albert Kheradpour, MD
COG-AAML1831
A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab oz ogamicin GO to CPX-351 with GO, and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations
https://clinicaltrials.gov/ct2/show/NCT04293562
Albert Kheradpour, MD
COG-AALL1621
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
https://clinicaltrials.gov/ct2/show/NCT02981628
Albert Kheradpour, MD
COG-AAML1921
A Phase I/II Study of Bosutinib in Pediatric Patients with Newly Diagnosed Chronic Phase or Resistant / Intolerant Ph+ Chronic Myeloid Leukemia
https://clinicaltrials.gov/ct2/show/NCT04258943
Albert Kheradpour, MD
COG-AALL1821
A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged 1-30 Years with First Relapse
https://clinicaltrials.gov/ct2/show/NCT04546399
Albert Kheradpour, MD
COG-AALL1731
A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
https://clinicaltrials.gov/ct2/show/NCT03914625
Albert Kheradpour, MD

Liver

COG-AHEP1531
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT) 
hhttps://clinicaltrials.gov/ct2/show/NCT03533582
Albert Kheradpour, MD

Lymphoma

COG-ACCL1333
A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B cell) treated with Pegylated (PEG) L-asparaginase
hhttps://clinicaltrials.gov/ct2/show/NCT03533582
Albert Kheradpour, MD
SWOG-S1826
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03907488
Albert Kheradpour, MD

Multiple

COG-APEC1621
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Master Version Control Document
https://clinicaltrials.gov/ct2/show/NCT03233204
Albert Kheradpour, MD

Neuroblastoma

COG-ANBL1232
Utilizing Response and Biology Based Risk Factors to Guide Therapy in Patients with Non-High Risk Neuroblastoma
https://clinicaltrials.gov/ct2/show/NCT02176967
Albert Kheradpour, MD
COG-ANBL1531
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)
https://clinicaltrials.gov/ct2/show/NCT03126916
Albert Kheradpour, MD

Rhabdomyosarcoma

COG-ARST1431
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
https://clinicaltrials.gov/ct2/show/NCT02567435
Albert Kheradpour, MD

Solid Tumors

COG-ADVL1711
A Phase 1/2 Study of Lenvatinib in combination with Everolimus in Recurrent and Refractory Pediatric Solid Tumors, including CNS tumors
https://clinicaltrials.gov/ct2/show/NCT03245151
Albert Kheradpour, MD

Stem Cell Transplant

NMDP-10-CBA
A Phase I/II Study of MK-3475 (Pembrolizumab) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051)
https://www.clinicaltrials.gov/ct2/show/NCT01351545
Albert Kheradpour, MD
NMDP-RESEARCH DATABASE
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
https://www.clinicaltrials.gov/ct2/show/NCT00495300
Albert Kheradpour, MD
NMDP-SAMPLE REPOSITORY
A Phase 2, multicenter, open-label study to assess safety and preliminary activity of eribulin mesylate in pediatric subjects with relapsed/refractory rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) and Ewing sarcoma (EWS)
https://www.clinicaltrials.gov/ct2/show/NCT00495300
Albert Kheradpour, MD
NMDP-17-SIBS
Identifying Predictors of Poor Health-R elated Quality-of-Life among Pediatric Hematopoietic Stem Cell Donor
https://www.clinicaltrials.gov/ct2/show/NCT03718546
Albert Kheradpour, MD
PBMTC-ONC1701
A phase II pilot trial to estimate survival after a non-total body irradiation (TBI) based conditioning regimen in patients diagnosed with B-acute lymphoblastic leukemia (ALL) who are pre-allogeneic hematopoietic cell transplantation (HCT) next-generation-sequence (NGS) minimal residual disease (MRD) negative.
https://clinicaltrials.gov/ct2/show/NCT0350961
Albert Kheradpour, MD

Wilms Tumor

COG-AREN1921
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
https://clinicaltrials.gov/ct2/show/NCT04322318
Albert Kheradpour, MD